Table 1.
No Adverse Outcome | Adverse Outcome | |
---|---|---|
Demographics | ||
Total number | 156 | 12 |
Male, n (%) | 67 (43%) | 5 (42%) |
Age (median, IQR) | 53 (40–66) | 58 (41–72) |
Comorbidities | ||
Cancer (%) | 52 (33%) | 4 (33%) |
Heart failure | 5 (3%) | 1 (8%) |
COPD | 4 (4%) | 5 (42%) |
Smoker | 56 (36%) | 5 (42%) |
Clinical findings | ||
Heart rate (median, IQR) | 96 (84–110) | 106 (99–119) |
Systolic BP mm Hg (median, IQR) | 135 (119–145) | 113 (97–149) |
Respiratory rate (median, IQR) | 18 (16–22) | 23(19–26) |
Altered mental status | 9 (6%) | 1 (8%) |
Pulse oximetry < 90% | 15 (10%) | 3 (25%) |
Interventions | ||
Heparin | 154 (99%) | 12 (100%) |
Echocardiogram | 45 (29%) | 7 (58%) |
IVC filter | 14 (9%) | 2 (17%) |
IQR = interquartile range; COPD = chronic obstructive pulmonary disease; BP = blood pressure; IVC = inferior vena cava.